US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’

ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.

PS1905_real-world-sign_164620043_1200.jpg
ICER Will Pilot Use Of RWE In Drug Assessment Updates

US commercial payers expect the Institute for Clinical and Economic Review’s efforts to update its cost effectiveness assessments using real world evidence could be the most impactful of the changes to its methodology implemented this year, according to a recently-released survey by contract research organization ICON.

The survey of 30 payers explored several aspects of ICER’s cost effectiveness methodology update for 2020-2023, which was released early this year

More from Real-World Evidence

More from Clinical Trials